# K171051: HORIZON Therapy System

- Pathway: 510(k) (Traditional)
- Applicant: Magstim Company, Ltd.
- Decided: Sep 13, 2017 after 156 days
- Product code: OBP (Transcranial Magnetic Stimulator)
- Device class: 2
- Regulation: 21 CFR 882.5805
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 6 generations back to DEN070003 (2008). 6 ancestors in all.
13 later devices descend from it; 1 cites it directly.
0 of 20 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- K143531: Rapid Therapy System, Magstim Company Limited (2015) Summary page 4.
- K162935: Rapid2 Therapy System, Magstim Company, Ltd. (2017) Summary page 4.

## Most influential descendants
- K180907: HORIZON TMS Therapy System (2018), 12 descendants of its own
- K182853: HORIZON TMS Therapy System (2019), 10 descendants of its own
- K183376: HORIZON TMS Therapy System with Navigation (2019), 7 descendants of its own
- K211389: Magstim Horizon 3.0 TMS Therapy System, Horizon 3.0 System, Horizon 3.0, Horizon 3.0 with Navigation (2021), 6 descendants of its own
- K222171: Magstim Horizon 3.0 TMS Therapy System, Horizon 3.0 System, Horizon 3.0, H3.0, Horizon 3.0 with StimGuide+ (2023), 4 descendants of its own

## Indications for use
The HORIZON™ Therapy System is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.

Source page: https://510kreport.com/device/K171051
Methodology: https://510kreport.com/methodology